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ments and adherence from June 2001 through December 2002.
Generalized Linear Models were estimated to examine the effects
of adherence on utilization patterns and expenditures in 2003.
RESULTS: Higher copayments led to lower levels of statin
adherence (Odds Ratio 0.75 p < 0.01 prevalent users, 0.72 p <
0.01 new users). For continuing users of statins higher levels of
statin adherence were associated with fewer adverse events: hos-
pitalizations (OR: 0.419 p = 0.01), cardiovascular hospitaliza-
tions (OR: 0.425 p = 0.046) and ER visits (OR: 0.219 p < 0.01).
Adherent patients had a larger number of physician ofﬁce visits
(OR: 14.84 p < 0.01 continuing users, 5.07 p < 0.01 new users)
and higher prescription drug expenditures (partial elasticity
0.204 p < 0.01 continuing users, 0.314 p < 0.01 new users).
However, medical expenditures and total (medical plus pre-
scription drug) expenditures for these patients were not signiﬁ-
cantly different from nonadherent patients. CONCLUSIONS:
Statin copayments serve as a ﬁnancial barrier to statin adherence.
Lower levels of adherence are associated with adverse cardio-
vascular and medical outcomes for patients remaining on statin
therapy. Policymakers and plan managers should consider effects
of higher statin copayments on adherence, utilization patterns
and clinical events.
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OBJECTIVES: Investigate how selection criteria and statistical
model speciﬁcations affect comparisons of alternative medica-
tions using retrospective database analyses. METHODS: Data
from the Medi-Cal Program were used to conduct a series of
head-to-head comparisons of alternative antipsychotics to test
the sensitivity of results to sample selection and model speciﬁ-
cation. OLS models were estimated for duration of therapy
deﬁned based on breaks in therapy >15 days. Five models were
compared: (1) a baseline model with only demographic inde-
pendent variables and selection criteria limited to age (18–100)
and prior eligibility >6 months; (2) screening for one year of
post-treatment data; (3) screening for schizophrenia; (4) addition
of prior diagnoses and utilization; and (5) addition of indepen-
dent variables for episode type. RESULTS: The baseline sample
consisted of 263,206 episodes. Average unadjusted days of
therapy for typical antipsychotics, olanzapine, risperidone and
quetiapine were 63, 138, 143 and 131, respectively. Model 1
found longer duration for all atypical antipsychotics relative to
conventional drugs (63–67 days). Risperidone exhibited longer
duration relative to olanzapine (+6 days, p < 0.0001) while olan-
zapine duration exceeded quetiapine by 8 days (p < 0.0001).
Duration for typicals increased from 63 days to 112 days in the
schizophrenia analysis (N = 70,650), reducing the estimated dif-
ferences favoring atypicals to 29–32 days (p < 0.0001). Adding
independent variables for prior utilization and diagnostic mix
reversed risperidone’s advantage over olanzapine from +6 to -4
days (p < 0.0001). Results favoring quetiapine over olanzapine
in duration of therapy on all antipsychotics was reversed from
+4 to +16 days to -3 days when covariates for episode type were
included in the model. CONCLUSIONS: Differences in duration
of antipsychotic therapy exist across diagnostic group and
episode type. Differences also exist in the diagnostic and episode
mix across drugs. Therefore, disaggregated patient samples and
expanded model speciﬁcations provide more accurate estimates
of differences in treatment duration.
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OBJECTIVES: To estimate the prevalence of diagnosis of atten-
tion-deﬁcit/hyperactivity disorder (ADHD) and use of stimulants
for children aged 3–18 years in the US ambulatory settings.
METHODS: Data from the National Ambulatory Medical Care
Survey (NAMCS) and the National Hospital Ambulatory
Medical Care Survey (NHAMCS) 1993–2003 were used. The
main outcome measures were annual visits with diagnosis of
ADHD, visits with prescription of stimulants, and proportion of
stimulants prescribed in visits with diagnosis of ADHD. Diag-
nosis of ADHD was determined using ICD-9-CM code 314.
Stimulants (methylphenidate, dexmethylphenidate, pemoline,
and amphetamine compounds) were identiﬁed by generic codes.
95% conﬁdence intervals were calculated and PROC SUR-
VEYFREQ in SAS 9.1 was used to account for the complex sam-
pling designs of these surveys. The results were weighted to
reﬂect national estimates. RESULTS: Outpatient visits made by
children 3–18 years of age increased from 131 (95% CI:
109–153) million in 1993 to 165 (137–192) million in 2003.
Diagnosis of ADHD increased 127%, from 3.2 (1.3–5.2) million
to 7.4 (5.2–9.5) million, accounted for 2.5% (1.0%–3.9%) and
4.5% (3.4%–5.6%) of all visits made by children in 1993 and
2003, respectively. Visits with stimulants prescribed jumped
from 2.7 (0.9–4.5) million in 1993 to 6.6 (4.5–8.7) million in
2003. Proportion of stimulant use in children doubled over this
period, from 2.1% (0.7%–3.4%) to 4.0% (3.0%–5.0%). Pro-
portion of children with ADHD treated with stimulants ranged
from 64.0% in 1997 to 77.3% in 1996, with an average of
70.4% (68.1%–72.8%) over the years studied. CONCLU-
SIONS: There was a steady growth in prevalence of ADHD and
stimulant use among children aged 3–18 years in the US between
1993 and 2003. Approximately 70% children with ADHD were
treated with stimulants. As appropriateness of treatment could
not be determined in the current databases, whether this per-
centage represents overutilization of underutilization of stimu-
lants merits further studies.
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OBJECTIVE: To assess the clinical characteristics and medica-
tion patterns of patients with schizophrenia treated with typical
depot antipsychotics compared with oral antipsychotics in the
usual care setting in Australia. METHODS: This was a prospec-
tive, single-site, observational study of 348 subjects with schiz-
ophrenia assessed at six-month intervals over three years. Data
were collected via face-to-face interviews by research personnel
and from external information systems to evaluate resource util-
isation. The two groups were compared for demographic and
clinical characteristics at baseline, co-therapy use, rate and
average length of stay (ALoS) of hospitalisation over the three
years. Analysis of variance was used to compare continuous vari-
ables, whereas the chi-square test was used for categorical out-
comes. RESULTS: A total of 144 and 179 patients were treated
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with depot and oral antipsychotics, respectively. 25 patients were
not treated with any antipsychotic medication, so were excluded
from the analyses. Compared with oral users, depot patients
were more likely to: have had more previous episodes of schiz-
ophrenia; have spent more days in hospital, be male; be less 
educated; be unemployed; be violent; and have experienced non-
violent crimes. Approximately 50% of all depot users were
treated with an oral antipsychotic supplement as co-therapy. A
higher proportion of depot users were admitted and re-admitted
to hospital throughout the study, with signiﬁcant differences in
year 2 and 3 (p < 0.01, respectively). The ALoS was consistently
higher in depot users compared with oral users over the three
years. CONCLUSION: Patients treated with typical depot
antipsychotics appear to be distinctly different from those treated
with oral antipsychotics. Depot users were found to consume
considerably more health care resources. This study indicates
that there may be a subset of the schizophrenia population whose
clinical needs are not currently well met by existing treatment
options.
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OBJECTIVE: The National Institute for Clinical Excellence’s
(NICE) initial evaluation of cholinesterase inhibitors for
Alzheimer’s disease failed to account for current guidance in the
UK, which states that only patients who respond to treatment
should continue with therapy. This study re-valuates cost-effec-
tiveness estimates using the same model in accordance with
current guidance. METHODS: The Assessment of Health Eco-
nomics in Alzheimer’s Disease (AHEAD) model, published in
2001, was adapted by the NICE appraisal group for their eval-
uation. The original AHEAD model was used to estimate the
cost-effectiveness of continuing therapy only in responders.
Where possible, model inputs were based on values used by
NICE. Only patients who experienced no decline in cognition
after six months of treatment with galantamine continued treat-
ment, for the subsequent ﬁve years. A health care payer per-
spective was adopted. Sensitivity analyses on costs, utilities,
discount rates, treatment effects and time horizon were con-
ducted. RESULTS: NICE reported the cost-effectiveness of
galantamine as £46,000 per discounted QALY gained in its aug-
mented base case results. Shadowing NICE inputs, and assum-
ing all patients continue with treatment regardless of response,
the original AHEAD model results in a ratio £32,000, so some
differences between the two analyses remain even when using
similar inputs. Using AHEAD, if only responders continue with
treatment, the ratio falls to £11,000, a 67% drop. If a respon-
der analysis in the NICE study would also result in a 67% reduc-
tion in their estimate, one would expect a new NICE ratio of
roughly £15,000. Treatment costs and time horizon were inﬂu-
ential. If projections are extended to 6 years, the ratio falls to
£7000. Varying the daily cost of galantamine by £0.50 changes
cost per QALY estimates by about £5000. CONCLUSIONS:
NICE’s initial cost-effectiveness assessment was not in agreement
with current guidance and results in inappropriately high esti-
mates of cost-effectiveness.
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OBJECTIVES: To compare 6-month medical costs and hospi-
talization risk of adults diagnosed with attention-deﬁcit/
hyperactivity disorder (ADHD) receiving extended-release
methylphenidate (OROS-MPH, CONCERTA®) to those receiv-
ing mixed amphetamine salts extended release (MAS-XR, 
Adderall XR®) or atomoxetine (Strattera®) from employer per-
spective. METHODS: We examined data from a U.S. employer
claims database of 5 million beneﬁciaries (1999–2004). Analysis
was restricted to adults aged 18–64 with at least one diagnosis
of ADHD (ICD-9: 314.x) and at least one prescription of OROS-
MPH, MAS-XR, or atomoxetine. Adults were required to have
continuous eligibility 6 months before and after their latest
therapy initiation and have no ADHD therapy in the prior 6
months. Descriptive measures of medical costs (including out-
patient and inpatient costs) and hospitalization risk were com-
puted over 6 months following therapy initiation. Generalized
estimating equations (GEE) models were used to compare costs
of adults receiving alternative therapies adjusting for baseline
demographic characteristics, substance abuse, depression, and
the Charlson comorbidity index. Costs were adjusted to 2004
dollars using medical CPI. RESULTS: Of the research sample (n
= 4569), 31.8% received OROS-MPH, 34.0% MAS-XR, and
34.2% atomoxetine. In the 6-month follow-up period, medical
costs were $1251 for OROS-MPH, $1422 for MAS-XR, and
$1581 for atomoxetine-treated adults. The GEE model adjust-
ing for patient characteristics found that 6-month medical costs
for OROS-MPH-treated adults were $141 less than for the MAS-
XR-treated (p = 0.02) and $132 less than for the atomoxetine-
treated (p = 0.03). The risk of having at least one hospitalization
was 42% higher for adults treated with MAS-XR (OR = 1.42,
95% CI: 0.99–2.05) and 51% higher for adults treated with ato-
moxetine (OR = 1.51, 95% CI: 1.05–2.17) compared to adults
treated with OROS-MPH. CONCLUSIONS: Over the 6-month
period after therapy initiation, adults treated with OROS-MPH
had lower medical costs than those treated with MAS-XR and
lower medical costs and risk of hospitalization than adults
treated with atomoxetine.
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OBJECTIVE: This analysis evaluated the medical cost savings of
delaying time to dialysis in elderly CKD patients receiving EPO.
METHODS: Using health claims and laboratory data from >35
health plans between January 1999 and April 2004, dialysis
patients (≥65 years) who had ≥1 hemoglobin (Hb) value and ≥1
glomerular ﬁltration rate (GFR) value <60mL/min prior to dial-
ysis were identiﬁed. Patients were excluded if they had an organ
transplant, had received blood transfusions or darbepoetin alfa,
or had received dialysis for non-CKD reasons. Each CKD patient
